Literature DB >> 12425870

Topical agents and erectile dysfunction: is there a place?

Ronald L Yap1, Kevin T McVary.   

Abstract

Despite the proven efficacy of oral therapy for erectile dysfunction (ED), some patients are unable to take these medications because of drug interactions (ie, sildenafil and nitroglycerin) or a lack of response. Topical agents represent another minimally invasive option for the treatment of ED. This review discusses the impediments to effective topical therapy and examines the developmental status of several candidate drugs. Although still in the investigative stage, topical medications can be another tool in the urologist's armamentarium against ED.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12425870     DOI: 10.1007/s11934-002-0100-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  32 in total

1.  Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction.

Authors:  D Schultheiss; D M Hiltl; M R Meschi; S A Machtens; M C Truss; C G Stief; U Jonas
Journal:  World J Urol       Date:  2000-12       Impact factor: 4.226

2.  Transcutaneous nitroglycerin therapy in the treatment of impotence.

Authors:  H Claes; L Baert
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

3.  The combined intracavernous injection and stimulation test: diagnostic accuracy.

Authors:  C F Donatucci; T F Lue
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

Review 4.  Developmental status of topical therapies for erectile and ejaculatory dysfunction.

Authors:  A Morales
Journal:  Int J Impot Res       Date:  2000-10       Impact factor: 2.896

5.  Intracavernous injection therapy: analysis of results and complications.

Authors:  M M Lakin; D K Montague; S VanderBrug Medendorp; L Tesar; L R Schover
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

6.  Topical minoxidil in the treatment of male erectile dysfunction.

Authors:  S B Radomski; S Herschorn; S Rangaswamy
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

7.  Papaverine and prostaglandin E1 gel applications for impotence.

Authors:  H S Chiang; Y H Kao; M T Sheu
Journal:  Ann Acad Med Singapore       Date:  1995-09       Impact factor: 2.473

Review 8.  Prostaglandin-induced neuropeptide release from spinal cord.

Authors:  M R Vasko
Journal:  Prog Brain Res       Date:  1995       Impact factor: 2.453

9.  Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence.

Authors:  G Cavallini
Journal:  J Urol       Date:  1991-07       Impact factor: 7.450

10.  Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury.

Authors:  M B Chancellor; D A Rivas; D E Panzer; M K Freedman; W E Staas
Journal:  Urology       Date:  1994-03       Impact factor: 2.649

View more
  3 in total

1.  Pharmacotherapy of sexual dysfunctions : current status.

Authors:  Ajith Avasthi; Parthasarathy Biswas
Journal:  Indian J Psychiatry       Date:  2004-07       Impact factor: 1.759

2.  Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction.

Authors:  George Han; Moses Tar; Dwaraka S R Kuppam; Adam Friedman; Arnold Melman; Joel Friedman; Kelvin P Davies
Journal:  J Sex Med       Date:  2009-09-18       Impact factor: 3.802

3.  Papaverine hydrochloride containing nanostructured lyotropic liquid crystal formulation as a potential drug delivery system for the treatment of erectile dysfunction.

Authors:  Szilvia Berkó; Stella Zsikó; Gábor Deák; Attila Gácsi; Anita Kovács; Mária Budai-Szűcs; László Pajor; Zoltán Bajory; Erzsébet Csányi
Journal:  Drug Des Devel Ther       Date:  2018-09-12       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.